\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\ \(73\)\
\-\ radiation\\ and\\ chemotherapy\\.\ \(10\)\
\-\ \\â\\€\\¢\\ february\\ mri\\ \\-\\ mesial\\ temporal\\ lobe\\ non\\ enhancing\\ lesion\\ on\\ the\\ left\\.\ \(0\)\
\-\ \\â\\€\\¢\\ june\\ mri\\ \\-\\ interval\\ development\\ of\\ multiple\\ enhancing\\ lesions\\ with\\ central\\ necrosis\\ in\\ left\\ hemisphere\\;\\ and\\,\\ dural\\ enhancement\\ overlying\\ left\\ frontal\\ and\\ parietal\\ lobe\ \(0\)\
\-\ multicentric\\ glioblastoma\\ multiforme\ \(0\)\
\-\ astrocytoma\ \(206\)\
\-\ metastatic\\ disease\ \(243\)\
\-\ lymphoma\ \(373\)\
\-\ 76\\ year\\ old\\ man\\ who\\ received\\ gamma\\ knife\\ radiation\\ 4\\ years\\ ago\\ for\\ left\\ sided\\ vestibular\\ schwannoma\\.\\ \\ now\\ presents\\ with\\ headache\\ and\\ vague\\ neurologic\\ complaints\\ for\\ three\\ months\\,\\ and\\ previous\\ abnormal\\ \\ mri\\ \\(see\\ below\\)\\ shows\\ abnormal\\ signal\\ in\\ medial\\ left\\ temporal\\ lobe\\ without\\ enhancement\\.\ \(0\)\
\-\ now\\ returns\\ with\\ worsening\\ symptoms\\.\ \(0\)\
\-\ this\\ patient\\ presents\\ 5\\ months\\ after\\ a\\ relatively\\ benign\\ looking\\ mri\\ with\\ multiple\\ cerebral\\ lesions\\ indicating\\ dramatic\\ progression\\ of\\ disease\\ in\\ the\\ brain\\ and\\ meninges\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ mri\\:\\ 0\\.05817113644191466\ \(0\)\
\-\ lobe\\:\\ 0\\.0510961188427452\ \(0\)\
\-\ temporal\\:\\ 0\\.050694679668357584\ \(0\)\
\-\ multicentric\\:\\ 0\\.04989686579471602\ \(0\)\
\-\ mesial\\:\\ 0\\.04902439886392799\ \(0\)\
\-\ returns\\:\\ 0\\.04575156366186103\ \(0\)\
\-\ february\\:\\ 0\\.045240505354550285\ \(0\)\
\-\ meninges\\:\\ 0\\.044313370962298385\ \(0\)\
\-\ now\\:\\ 0\\.04327578651409848\ \(0\)\
\-\ radiation\\:\\ 0\\.04154446295647906\ \(0\)\
\-\ june\\:\\ 0\\.041456611845172575\ \(0\)\
\-\ dramatic\\:\\ 0\\.040886530058979034\ \(0\)\
\-\ looking\\:\\ 0\\.04010608179484698\ \(0\)\
\-\ knife\\:\\ 0\\.03986319421838039\ \(0\)\
\-\ enhancing\\:\\ 0\\.039703015301996436\ \(0\)\
\-\ gamma\\:\\ 0\\.038355053809186024\ \(0\)\
\-\ multiforme\\:\\ 0\\.03678052460930696\ \(0\)\
\-\ vestibular\\:\\ 0\\.03632218828546927\ \(0\)\
\-\ abnormal\\:\\ 0\\.036105070226887574\ \(0\)\
\-\ 76\\:\\ 0\\.03575210649927573\ \(0\)\
\-\ left\\:\\ 0\\.03541130626936721\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.03484921896143101\ \(0\)\
\-\ months\\:\\ 0\\.03457690806948248\ \(0\)\
\-\ vague\\:\\ 0\\.03404452384289179\ \(0\)\
\-\ enhancement\\:\\ 0\\.03393316690552646\ \(0\)\
\-\ lesions\\:\\ 0\\.033889785279169596\ \(0\)\
\-\ indicating\\:\\ 0\\.03265777167927589\ \(0\)\
\-\ hemisphere\\:\\ 0\\.03221933559490307\ \(0\)\
\-\ progression\\:\\ 0\\.03149014987036046\ \(0\)\
\-\ interval\\:\\ 0\\.031041078597646127\ \(0\)\
\-\ dural\\:\\ 0\\.030686589551885864\ \(0\)\
\-\ received\\:\\ 0\\.02941726916672524\ \(0\)\
\-\ schwannoma\\:\\ 0\\.028910100283188495\ \(0\)\
\-\ overlying\\:\\ 0\\.028642655804358\ \(0\)\
\-\ development\\:\\ 0\\.027568653504886933\ \(0\)\
\-\ complaints\\:\\ 0\\.027478318148636428\ \(0\)\
\-\ below\\:\\ 0\\.027478318148636428\ \(0\)\
\-\ \\-\\:\\ 0\\.02713671790679057\ \(0\)\
\-\ relatively\\:\\ 0\\.027084912035199773\ \(0\)\
\-\ parietal\\:\\ 0\\.027042462592910994\ \(0\)\
\-\ multiple\\:\\ 0\\.02666379264413732\ \(0\)\
\-\ neurologic\\:\\ 0\\.02643329149485935\ \(0\)\
\-\ non\\:\\ 0\\.026165294038729702\ \(0\)\
\-\ presents\\:\\ 0\\.025861396970487793\ \(0\)\
\-\ necrosis\\:\\ 0\\.024985931210701518\ \(0\)\
\-\ worsening\\:\\ 0\\.024922073854820724\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.024580371842024416\ \(0\)\
\-\ previous\\:\\ 0\\.024580371842024416\ \(0\)\
\-\ ago\\:\\ 0\\.02356095422812777\ \(0\)\
\-\ sided\\:\\ 0\\.0234039008381233\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.02321502743105019\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.022688487297339743\ \(0\)\
\-\ cerebral\\:\\ 0\\.021929233346400526\ \(0\)\
\-\ benign\\:\\ 0\\.02184481753357927\ \(0\)\
\-\ headache\\:\\ 0\\.021740632870857764\ \(0\)\
\-\ three\\:\\ 0\\.02133795724701415\ \(0\)\
\-\ available\\:\\ 0\\.021279400361776276\ \(0\)\
\-\ central\\:\\ 0\\.020826898939703402\ \(0\)\
\-\ disease\\:\\ 0\\.020692408018010432\ \(0\)\
\-\ medial\\:\\ 0\\.020246663063630016\ \(0\)\
\-\ frontal\\:\\ 0\\.019883643959135982\ \(0\)\
\-\ brain\\:\\ 0\\.0190470483207612\ \(0\)\
\-\ see\\:\\ 0\\.018890497860953988\ \(0\)\
\-\ years\\:\\ 0\\.018586986200136907\ \(0\)\
\-\ 5\\:\\ 0\\.01851970683291973\ \(0\)\
\-\ lymphoma\\:\\ 0\\.018090360254736933\ \(0\)\
\-\ 4\\:\\ 0\\.01763682892725219\ \(0\)\
\-\ shows\\:\\ 0\\.017402768146139842\ \(0\)\
\-\ signal\\:\\ 0\\.016689439483502065\ \(0\)\
\-\ who\\:\\ 0\\.01650346969734594\ \(0\)\
\-\ metastatic\\:\\ 0\\.01593414373048956\ \(0\)\
\-\ symptoms\\:\\ 0\\.015775240569615847\ \(0\)\
\-\ \\;\\:\\ 0\\.015003119914463658\ \(0\)\
\-\ man\\:\\ 0\\.014969865504370366\ \(0\)\
\-\ without\\:\\ 0\\.014903801232282668\ \(0\)\
\-\ after\\:\\ 0\\.01309630520451261\ \(0\)\
\-\ lesion\\:\\ 0\\.012893001674077443\ \(0\)\
\-\ for\\:\\ 0\\.010801602202114298\ \(0\)\
\-\ in\\:\\ 0\\.009364382892005665\ \(0\)\
\-\ not\\:\\ 0\\.009146804975866188\ \(0\)\
\-\ and\\:\\ 0\\.008000400254765266\ \(0\)\
\-\ this\\:\\ 0\\.0071195349134380225\ \(0\)\
\-\ year\\:\\ 0\\.0070822612538734425\ \(0\)\
\-\ old\\:\\ 0\\.006480997013794479\ \(0\)\
\-\ patient\\:\\ 0\\.006345125414195467\ \(0\)\
\-\ on\\:\\ 0\\.005362155647151319\ \(0\)\
\-\ \\(\\:\\ 0\\.0053508276018063745\ \(0\)\
\-\ \\)\\:\\ 0\\.0052854643860244825\ \(0\)\
\-\ \\,\\:\\ 0\\.0040105194891449985\ \(0\)\
\-\ with\\:\\ 0\\.0034667904026633996\ \(0\)\
\-\ a\\:\\ 0\\.002937776309767417\ \(0\)\
\-\ the\\:\\ 0\\.0020481375511648267\ \(0\)\
\-\ of\\:\\ 0\\.0017259822340442731\ \(0\)\
\-\ \\.\\:\\ 0\\.0015777571598820568\ \(0\)\
